In the CheckMate 227 (NCT02477826) Part 1 trial, OS of patients with metastatic non-small-cell lung cancer treated with nivolumab plus ipilimumab was compared with chemotherapy regardless of tumor programmed death ligand 1 (PD-L1) expression status. The gene discussed is CD274; the disease is non-small cell lung carcinoma.